GlassScriptPhysician profile
John H Hayden
NPI 1598721243
$4,457.74
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $1,059 · 2021: $1,071 · 2022: $1,405 · 2023: $433 · 2024: $39.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $820.51 | 2019-2023 | Farxiga, Breztri |
| Lilly USA, LLC | $361.19 | 2019-2023 | Mounjaro, Jardiance |
| Abbvie INC. | $358.84 | 2021-2024 | |
| Esperion Therapeutics, INC. | $259.26 | 2020-2023 | Nexletol |
| Inari Medical, INC. | $231.14 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $228.46 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $179.24 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $170.77 | 2020-2023 | Trintellix |
| Novo Nordisk INC | $170.58 | 2019-2022 | |
| Amarin Pharma, INC. | $154.85 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $143.23 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.06 | 2019-2023 | Tradjenta, Jardiance |
| Glaxosmithkline, LLC. | $121.78 | 2020-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Arbor Pharmaceuticals, INC. | $105.06 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $92.47 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $88.27 | 2019-2021 | |
| Zealand Pharma US, INC. | $81.66 | 2020-2022 | |
| Silk Road Medical, INC. | $79.92 | 2020 | |
| Eisai INC. | $74.26 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $73.56 | 2022-2023 | Gvoke Hypopen |
| Valeritas, INC. | $70.68 | 2019 | |
| Nestle Healthcare Nutrition INC. | $58.50 | 2021-2022 | |
| Insulet Corporation | $51.33 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $48.65 | 2019-2022 | |
| Horizon Therapeutics Plc | $47.40 | 2020-2021 | |
| Genentech USA, INC. | $39.03 | 2020-2021 | |
| Antares Pharma, INC. | $32.94 | 2022 | |
| Pfizer INC. | $32.78 | 2023 | |
| Amgen INC. | $28.15 | 2019 | |
| Lundbeck LLC | $26.18 | 2022 | |
| Medtronic, INC. | $16.95 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.52 | 2023 | Quviviq |
| Abbott Laboratories | $14.06 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.04 | 2021 | |
| Tolmar, INC. | $12.76 | 2023 | |
| Shield Therapeutics INC | $12.71 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hayden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.